Platelet [3H]imipramine and [3H]paroxetine binding in depressed patients

Rosel, Pilar; Menchón, José M.; Vallejo, Julio; Arranz, Belén; Navarro, M. A.; Lirón, F J.; Álvarez, Pilar

doi:10.1016/s0165-0327(97)00033-5

Cited by 18 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings cannot be attributed to methodological interferences (Rosel et al, 1995). Similar results by our group have shown variations in [3H]imipramine but not in [3H]paroxetine binding in blood platelets from depressed patients (Rosel et al, 1997b), which is in agreement with other published results (SuranyiCadote et al, 1989;Inyl et al, 1989).…”

Section: Discussionsupporting

confidence: 94%

High affinity [3H]imipramine and [3H]paroxetine binding sites in suicide brains

Rosel

Arranz

Vallejo

et al. 1997

J. Neural Transmission

View full text Add to dashboard Cite

Specific binding of [3H]imipramine and [3H]paroxetine was simultaneously examined in human brains (frontal cortex, temporal cortex, cingulate cortex, hypothalamus, hippocampus and amygdala) from 11 controls and 11 depressed suicide victims. A single saturable high affinity site was obtained for both radioligands. Age was not related to significant changes in [3H]imipramine and [3H]paroxetine binding parameters, which indicates the stability of the brain serotonergic system with increasing age. A major finding of the present study concerns the existence of a significant decrease in the maximum number (Bmax) of [3H]imipramine binding sites in hippocampus from depressed suicides as compared with the control group, without changes in the binding affinity (Kd). In contrast, when [3H]paroxetine was used as radioligand, no changes in either Bmax or Kd were detected in any of the brain regions studied. These findings suggest that [3H]imipramine may be a better marker than [3H]paroxetine when alterations in the presynaptic serotonergic uptake site are to be detected.

show abstract

Section: Discussionsupporting

confidence: 94%

High affinity [3H]imipramine and [3H]paroxetine binding sites in suicide brains

Rosel

Arranz

Vallejo

et al. 1997

J. Neural Transmission

View full text Add to dashboard Cite

show abstract

“…Notably, a decline of receptor/transporter densities with age has been observed with multiple neurotransmitter systems [184][185][186][187][188][189][190][191][192][193]. Interestingly, major depressive disorders (MDD) [194,195], bipolar disorder [196], obsessive-compulsive disorder (OCD) [197], eating disorders [198] and autism [199,200] have recently been associated with reductions in regional brain volume and/or ventricular enlargement.…”

Section: The Serotonin Transporter Under Changing Physiological Condimentioning

confidence: 99%

Neuroimaging of the Serotonin Transporter: Possibilities and Pitfalls

Brust¹,

Hesse²,

Müller³

et al. 2006

CPSR

View full text Add to dashboard Cite

Nuclear medicine imaging techniques like positron emission tomography (PET) and single-photon emission computed tomography (SPECT) apply radiolabeled drugs that bind selectively to specific neurotransmitter receptors and transporters such as the serotonin transporter (SERT) in the living human brain. They can help overcome certain limitations of postmortem, platelet and genetic studies of the SERT. This review compares the outcome of those studies with recent neuroimaging findings. The first part of this review deals with the choice of radioligands used to quantify SERT distribution in the human brain. The second part summarizes studies performed to understand the normal physiology of the serotonergic system. Selective serotonin reuptake inhibitors (SSRIs), used to treat a wide range of neuropsychiatric disorders with emotional instability and behavioral control deficits, compete with SERT radioligands and have been investigated in pharmacological PET and SPECT studies in healthy volunteers and patients. Part three reviews SERT imaging studies in patients, which have meanwhile been performed in most disorders that benefit from SSRI treatment. It is hypothesized that serotonin deficits and neuropsychiatric symptoms are linked by the inhibition of involuntary emotional reactions to external and internal stimuli. This could explain, why the consistency of many SERT neuroimaging findings is low, and may help develop individual treatment strategies in therapy-nonresponsive cases and to engineer new drugs for the therapy of neuropsychiatric disorders.

show abstract

“…Indeed, studies on the relationship between depression and platelet paroxetine binding have been inconsistent (Rosel et al 1997(Rosel et al , 1999.…”

Section: Discussionmentioning

confidence: 99%